Dr Nick Johnson appointed as Chief Strategy and Impact Officer of CGT Catapult
pharmafile | October 8, 2020 | Appointment | Business Services |
Dr Nick Johnson has been appointed the Chief Strategy and Impact Officer of the Cell and Gene Therapy Catapult.
Johnson was previously the Commercial Director at the Centre for Process Innovation which is part of the High Value Manufacturing Catapult.
Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult, said: “Nick is a wonderful addition to our leadership team. He brings over 25 years of experience in delivering pharmaceutical and commercial value, on top of the know-how of having worked for another highly impactful Catapult with strong focus on innovation and partnerships. The team is very much looking forward to welcoming Nick in this new role.”
Before joining CGT, Johnson had been in director roles at Johnson Matthey and Catalent as well as SAFC. In his new role, Johnson will focus on aligning with the government’s goal to grow the UK’s cell and gene therapy industry.
Johnson commented on his appointment, and said: “I am extremely excited to be joining the Cell and Gene Therapy Catapult at such an exciting time, in order to help the company continue to support the growing network of organisations dedicated to discovering, developing and commercialising cell and gene therapies. These innovations are truly life changing, bringing the hope of treatments or even cures for serious diseases where previously there have been no effective interventions.”